FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells

Several reports suggest that malignant cells generate phenotypic diversity through fusion with various types of stromal cells within the tumor microenvironment. Mesenchymal stem cell (MSC) is one of the critical components in the tumor microenvironment and a promising fusogenic candidate, but the underlying functions of MSC fusion with malignant cell have not been fully examined. Here, we demonstrate that MSCs fuse spontaneously with lung cancer cells, and the latter is reprogrammed to slow growth and stem-like state. Transcriptome profiles reveal that lung cancer cells are reprogrammed to a more benign state upon MSC fusion. We further identified FOXF1 as a reprogramming mediator that contributes not only to the reprogramming toward stemness but also to the p21-regulated growth suppression in fusion progeny. Collectively, MSC fusion does not enhance the intrinsic malignancy of lung cancer cells. The anti-malignant effects of MSC fusion-induced reprogramming on lung cancer cells were accomplished by complementation of tumorigenic defects, including restoration of p21 function and normal terminal differentiation pathways as well as up-regulation of FOXF1, a putative tumor suppressor. Such fusion process raises the therapeutic potential that MSC fusion can be utilized to reverse cellular phenotypes in cancer.

[1]  Shuying Yang,et al.  Advances in Reprogramming Somatic Cells to Induced Pluripotent Stem Cells , 2010, Stem Cell Reviews and Reports.

[2]  Z. Ju,et al.  Fusion of human umbilical cord mesenchymal stem cells with esophageal carcinoma cells inhibits the tumorigenicity of esophageal carcinoma cells. , 2011, International journal of oncology.

[3]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[4]  Rolf Bjerkvig,et al.  Opinion: the origin of the cancer stem cell: current controversies and new insights. , 2005, Nature reviews. Cancer.

[5]  Pang-Kuo Lo,et al.  The p53-p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function. , 2012, Cellular signalling.

[6]  K. Horwitz,et al.  Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. , 2006, Cancer research.

[7]  Tomas W. Fitzgerald,et al.  Genomic and Genic Deletions of the FOX Gene Cluster on 16q24.1 and Inactivating Mutations of FOXF1 Cause Alveolar Capillary Dysplasia and Other Malformations , 2009, American journal of human genetics.

[8]  D. Banerjee,et al.  Differential Gene Expression Associated with Migration of Mesenchymal Stem Cells to Conditioned Medium from Tumor Cells or Bone Marrow Cells , 2007, Stem cells.

[9]  P. Carlsson,et al.  Haploinsufficiency of the forkhead gene Foxf1, a target for sonic hedgehog signaling, causes lung and foregut malformations. , 2001, Development.

[10]  N. Miller,et al.  Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT) , 2010, Breast Cancer Research and Treatment.

[11]  T. Lai,et al.  The role of the ERK1/2 pathway as an alternative to the aging-diminished cyclic AMP pathway in calcitonin-mediated chondrogenesis in human nucleus pulposus. , 2012, Biomaterials.

[12]  Yan Zhou,et al.  Foxf1 +/− mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury , 2003, Hepatology.

[13]  M. Andreeff,et al.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. , 2002, Cancer research.

[14]  S. Hung,et al.  Mesenchymal Stem Cell Targeting of Microscopic Tumors and Tumor Stroma Development Monitored by Noninvasive In vivo Positron Emission Tomography Imaging , 2005, Clinical Cancer Research.

[15]  Y. Lazebnik,et al.  Cell fusion: a hidden enemy? , 2003, Cancer cell.

[16]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[17]  Xin Lu,et al.  Cell fusion as a hidden force in tumor progression. , 2009, Cancer research.

[18]  E. Lam,et al.  Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth , 2007, Leukemia.

[19]  T. Dittmar,et al.  Fusion of CCL21 Non-Migratory Active Breast Epithelial and Breast Cancer Cells Give Rise to CCL21 Migratory Active Tumor Hybrid Cell Lines , 2013, PloS one.

[20]  P. Lesault,et al.  Human Mesenchymal Stem Cells Reprogram Adult Cardiomyocytes Toward a Progenitor‐Like State Through Partial Cell Fusion and Mitochondria Transfer , 2011, Stem cells.

[21]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[22]  D. Cleveland,et al.  Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis , 2009, Nature Reviews Molecular Cell Biology.

[23]  A. Chakraborty,et al.  Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis , 2008, Nature Reviews Cancer.

[24]  J. Platt,et al.  Biological implications of cell fusion , 2005, Nature Reviews Molecular Cell Biology.

[25]  Erika Pastrana,et al.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells. , 2011, Cell stem cell.

[26]  H Harris,et al.  The analysis of malignancy by cell fusion. I. Hybrids between tumour cells and L cell derivatives. , 1971, Journal of cell science.

[27]  H. Harris The Analysis of Malignancy by Cell Fusion: the Position in Updated Version Citing Articles E-mail Alerts , 2013 .

[28]  A. Chinnaiyan,et al.  Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23–qter and identifies underlying candidate tumor suppressor genes in prostate cancer , 2004, Oncogene.

[29]  Rolf Bjerkvig,et al.  The origin of the cancer stem cell: current controversies and new insights , 2005, Nature Reviews Cancer.

[30]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[31]  J. Selbig,et al.  Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro , 2012, Experimental Neurology.

[32]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[33]  Roopa R. Nadig Stem cell therapy – Hype or hope? A review , 2009, Journal of conservative dentistry : JCD.

[34]  M. Cosma,et al.  Cell‐fusion‐mediated somatic‐cell reprogramming: A mechanism for tissue regeneration , 2010, Journal of cellular physiology.

[35]  F. Douglas,et al.  The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  L. Larsson,et al.  Spontaneous fusion between cancer cells and endothelial cells , 2004, Cellular and Molecular Life Sciences CMLS.

[37]  T. Hunt,et al.  Bone Marrow Contribution to Tumor-Associated Myofibroblasts and Fibroblasts , 2004, Cancer Research.

[38]  F. Djouad,et al.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.

[39]  Catherine M. Verfaillie,et al.  Pluripotency of mesenchymal stem cells derived from adult marrow , 2007, Nature.

[40]  L. Busund,et al.  Spontaneously formed tumorigenic hybrids of Meth A sarcoma cells and macrophages in vivo , 2003, International journal of cancer.

[41]  D. Curiel,et al.  Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses , 2006, Molecular Cancer Therapeutics.

[42]  G. Dontu,et al.  Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. , 2011, Cancer research.

[43]  B. Brandt,et al.  Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells , 2010, Clinical & Experimental Metastasis.

[44]  M. Qumsiyeh,et al.  Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT–tumor hybrids by FISH , 2005, Bone Marrow Transplantation.

[45]  Maria Pia Cosma,et al.  Cell-fusion-mediated reprogramming: pluripotency or transdifferentiation? Implications for regenerative medicine. , 2011, Advances in experimental medicine and biology.

[46]  M. Andreeff,et al.  Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. , 2005, Cancer research.

[47]  Pang-Kuo Lo,et al.  Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. , 2010, Cancer research.

[48]  Xin Lu,et al.  Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants , 2009, Proceedings of the National Academy of Sciences.

[49]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[50]  K Watanabe,et al.  Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  F. Pontén,et al.  Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient , 2004, Bone Marrow Transplantation.

[52]  A. Rizvi,et al.  Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Q. Ye,et al.  Mesenchymal stem cells seldomly fuse with hepatocellular carcinoma cells and are mainly distributed in the tumor stroma in mouse models. , 2013, Oncology reports.

[54]  Shiaw-Min Hwang,et al.  Establishment of immortalized mesenchymal stromal cells with red fluorescence protein expression for in vivo transplantation and tracing in the rat model with traumatic brain injury. , 2010, Cytotherapy.

[55]  V. Keshamouni,et al.  Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts. , 2011, The American journal of pathology.

[56]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[57]  R. O’Neill,et al.  Genome‐Wide Reprogramming in Hybrids of Somatic Cells and Embryonic Stem Cells , 2007, Stem cells.

[58]  E. Scott,et al.  Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion , 2002, Nature.

[59]  Dominic J. Ambrosi,et al.  Reprogramming mediated by stem cell fusion , 2005, Journal of cellular and molecular medicine.

[60]  M. Terry,et al.  Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency based reprogramming , 2012, Oncogene.

[61]  S. Sell Adult stem cell plasticity , 2007, Stem Cell Reviews.

[62]  B. Brandt,et al.  Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk , 2012, Cell Communication and Signaling.

[63]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[64]  S. Chiou,et al.  Mesenchymal stem cells promote formation of colorectal tumors in mice. , 2011, Gastroenterology.